Harrisvaccines announced Oct. 29 that it has expanded its exclusive license agreement with AlphaVax Inc. to include all companion animal diseases, in addition to all livestock animal diseases (swine, cattle, horses, poultry and farmed aquatic animals).
The agreement "significantly expands" the Harrisvaccines product portfolio, transforming it from a primarily production livestock-focused company to a full-service veterinary animal health company, developing vaccines for animals large and small, the announcement said.
Harrisvaccines said it will begin its work in the companion animal realm by developing vaccines for a variety of respiratory diseases in dogs.
"This is a significant milestone for Harrisvaccines and solidifies our place as an innovative leader in the biologics industry with the ability to utilize this novel, exclusive technology in all preventive veterinary aspects," Joel Harris, head of sales and marketing for Harrisvaccines, said.
Harrisvaccines' RNA Particle (RP) Platform technology utilizes a genetic sequence of specific viruses, which can be submitted electronically, to create a vaccine. Harrisvaccines can use this technology to develop strain-specific vaccines in just a matter of weeks, allowing for rapid response to disease outbreaks. As diseases are constantly evolving, this is crucial to containment and eradication efforts.
In September 2012, Harrisvaccines received its first license from the U.S. Department of Agriculture for its RP vaccine for H3N2 Influenza Virus in swine, the first vaccine of its kind using this RP technology to be licensed by a government agency.
Harrisvaccines has developed and commercialized vaccines for some of the most economically significant swine diseases to date, including porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus, pandemic H1N1 swine influenza virus and porcine rotavirus A, B, and C.